Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY:ABT)

100.75 +0.24 (+0.24%)
Delayed Quote Updated: 9:49 AM EDT, Oct 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Abbott Laboratories

< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
News headline image
Abbott: 3 Key Takeaways for Long-Term Investors ↗
Pulsed field ablation and expanded cancer screening tools position the core business for accelerated growth beyond historical rates. 
Via The Motley Fool
Topics Earnings
S&P 500 Top Movers: Oct. 21, 2026 US Session ↗
Via Chartmill
Topics Stocks
News headline image
Abbott (ABT) Q3 2026 Earnings Call Transcript ↗
Abbott plans nutrition spinoff by end of 2027 amid strong Q3 growth. 
Via The Motley Fool
Topics Earnings
S&P 500 Unusual Volume Movers: Oct. 21, 2026 ↗
Via Chartmill
Topics Stocks
Abbott Laboratories (NYSE:ABT) Posts In-Line Q3 Results as Reaffirmed Guidance and Nutrition Separation Pressure Shares ↗
Via Chartmill
Abbott Laboratories (NYSE:ABT): A Quality Stock With Durable Fundamentals ↗
Via Chartmill
News headline image
What Abbott Laboratories (ABT) Said on Its Q3 Earnings Call ↗
Abbott Laboratories (NYSE:ABT) reported third-quarter sales growth of 7% and adjusted earnings-per-share growth of 9%, while announcing plans to separate its nutrition business into an independent... 
Via MarketBeat
Topics Earnings
S&P 500 Top Movers on Oct. 21, 2026: Supermicro Leads Gainers, Dexcom Leads Losers ↗
Via Chartmill
Topics Stocks
News headline image
Abbott Laboratories’s (NYSE:ABT) Q3 2026 earnings results: revenue in line with expectations
Healthcare product and device company Abbott Laboratories (NYSE:ABT) met Wall Street’s revenue expectations in Q3 2026, with sales up 14.5% year on year to $... 
Via StockStory
S&P 500 Premarket Movers on Oct. 21: Tech Hardware and AI Suppliers Gain, Health Care Declines ↗
Via Chartmill
Topics Artificial Intelligence Stocks Supply Chain
S&P 500 Top Movers: EFX and HAS Lead Today's Gainers, GM and DVA Fall ↗
Via Chartmill
Topics Stocks
News headline image
Ken Griffin Increased His Position in This Dividend King by a Whopping 546% in Q2. Here's Why It's Still a Buy. ↗
It was Griffin's biggest add for Citadel last quarter. 
Via The Motley Fool
Topics Economy
News headline image
I Just Invested $4,600 Across 3 Top Dividend Stocks. Here’s What I’m Loading Up on Right Now. ↗
These companies pay durable and growing dividends. 
Via The Motley Fool
Topics Economy
News headline image
Forget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle ↗
Rising rates can expose dividend traps, but this Dividend King is built to keep paying. 
Via The Motley Fool
Topics Credit Cards
News headline image
The Market Is Flashing Warning Signals Not Seen in Years. Here’s Why I Just Bought 3 of SCHD’s Dividend Kings. ↗
The market's warning signs are driving me to shift my portfolio towards high-quality holdings. 
Via The Motley Fool
Topics ETFs Economy
News headline image
Want Passive Income for Life? Here Are 2 Dividend Stocks to Buy and Never Sell ↗
These companies have a long history of dividend growth. 
Via The Motley Fool
News headline image
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026? ↗
Abbott trades at a 18x forward P/E with $7.4B in free cash flow, while Intuitive Surgical commands a 39x multiple backed by zero debt and 20% revenue growth. 
Via The Motley Fool
News headline image
AbbVie's Dividend Yield Is at Its Lowest Level Since 2018. Here's Why the Stock Is Still a Great Pick for Income Investors Anyway. ↗
A super-high yield isn't everything. 
Via The Motley Fool
Topics Intellectual Property
News headline image
How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends? ↗
You'll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb. 
Via The Motley Fool
Topics Intellectual Property
News headline image
History Says Abbott Stock Could More Than Double by 2036. Here’s Why I Just Added It to My Portfolio. ↗
Abbott has a low-risk profile with significant upside potential. 
Via The Motley Fool
News headline image
These 3 Dividend Stocks Yield Less Than 10-Year Treasuries Over 5%. Here's Why They Are Better Buys Anyway. ↗
Treasuries pay more today, but these three healthcare dividend payers offer something Treasuries can't: growth in both the payout and the stock. 
Via The Motley Fool
News headline image
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026? ↗
Intuitive Surgical is beating estimates and raising margins while its installed base keeps expanding. Abbott is executing steadily across a diversified portfolio but growing at a more measured pace. 
Via The Motley Fool
News headline image
Want a Portfolio That Pays You $1,000 a Month in Passive Income? This Dividend ETF Could Get You There. ↗
It's as stable and consistent as you'd hope from a dividend ETF. 
Via The Motley Fool
Topics ETFs
News headline image
Prediction: Here's What $10,000 Invested in AbbVie Stock With Dividends Reinvested Could Be Worth in a Decade ↗
It would be hard for investors to replicate the company's return over the past decade. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 High-Yielding Dividend Stocks That Are No-Brainer Buys for Retirees and Risk-Averse Investors ↗
These quality, low-volatility stocks yield between 2.4% and 3.1%, and have been raising their payouts for decades. 
Via The Motley Fool
News headline image
Abbott Laboratories vs. Intuitive Surgical: Recent Quarterly Revenue Trends Reveal a Classic Investing Truth ↗
Abbott leads in absolute revenue, but Intuitive Surgical's growth rate tells a different story over the past eight quarters. 
Via The Motley Fool
Topics Product Recall
News headline image
3 Dividend Stocks to Buy and Hold for 10 Years ↗
They have a knack for increasing their dividends even when facing challenges. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Why Wall Street Is Becoming Even More Bullish About This Dividend King ↗
Analysts keep raising their price targets on this 54-year dividend raiser. Here are the reasons behind the newfound confidence. 
Via The Motley Fool
News headline image
JEPI and JEPQ Yield Way More Than SCHD, but SCHD Could Produce More Passive Income Over the Long Term. Here's Why. ↗
Long-term holders of the Schwab U.S. Dividend Equity ETF have seen their yield on cost gradually rise. 
Via The Motley Fool
Topics Bonds ETFs Regulatory Compliance
News headline image
Is AbbVie the Best Dividend King to Buy in September? ↗
It is certainly a good Dividend King to buy in September. 
Via The Motley Fool
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.